A critical evaluation of glycated protein parameters in advanced nephropathy: A matter of life or death. Time to dispense with the hemoglobin A1C in end-stage kidney disease

Diabetes Care

Volumn 35, Issue 7, 2012, Pages 1621-1624

  Freedman, Barry I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FRUCTOSAMINE; GLUCOSE; GLYCOSYLATED ALBUMIN; GLYCOSYLATED PROTEIN; HEMOGLOBIN; HEMOGLOBIN A1C;

ALBUMIN BLOOD LEVEL; ALBUMINURIA; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; DEATH; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIALYSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; LIFE EXPECTANCY; MEDICAL INFORMATION; MORTALITY; NUTRITIONAL STATUS; PATIENT CARE; PREDICTION; PREDICTIVE VALUE; REVIEW; RISK REDUCTION; SURVIVAL RATE;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 84862859086     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0027     Document Type: Review

References (28)

1. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559 (Pubitemid 351831356)
2. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
3. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360: 129-139
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
5. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167
6. Riddle MC, Ambrosius WT, Brillon DJ, et al.; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year followup of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-990
7. Shima K, Chujo K, Yamada M, Komatsu M, Noma Y, Mizuguchi T. Lower value of glycated haemoglobin relative to glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis. Ann Clin Biochem 2012;49:68-74
8. Inaba M, Okuno S, Kumeda Y, et al.; Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896-903 (Pubitemid 46434506)
9. Freedman BI, Shenoy RN, Planer JA, et al. Comparison of glycated albumin and hemoglobin A1C concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int 2010;30:72-79
10. Freedman BI, Shihabi ZK, Andries L, et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol 2010;31: 375-379
11. Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008;73: 1062-1068 (Pubitemid 351543905)
12. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007; 30:1049-1055 (Pubitemid 46684623)
13. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis 2011;58:591-598
14. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 2006;70:1503-1509 (Pubitemid 44527322)
15. Williams ME, Lacson E Jr, Wang W, Lazarus JM, Hakim R. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and timedependent Cox model analyses. Clin J Am Soc Nephrol 2010;5:1595-1601
16. Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis 2010;55:875-884
17. Wanner C, Krane V, März W, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248 (Pubitemid 41058323)
18. Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol 2011;6:1041-1048
19. U.S.Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, Maryland, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 2010, p. 121-132
20. Mehrotra R, Kalantar-Zadeh K, Adler S. Assessment of glycemic control in dialysis patients with diabetes: glycosylated hemoglobin or glycated albumin? Clin J Am Soc Nephrol 2011;6:1520-1522
21. Freedman BI, Andries L, Shihabi ZK, et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011;6: 1635-1643
22. Fukuoka K, Nakao K, Morimoto H, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 2008; 13:278-283 (Pubitemid 351668328)
23. Kohzuma T, Yamamoto T, Uematsu Y, Shihabi ZK, Freedman BI. Basic performance of an enzymatic method for glycated albumin and reference range determination. J Diabetes Sci Technol 2011;5:1455-1462
24. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761-1773 (Pubitemid 38857461)
25. Riveline JP, Teynie J, Belmouaz S, et al. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant 2009;24:2866-2871
26. Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 2009;32:1137-1142
27. Mittman N, Desiraju B, Fazil I, et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int Suppl 2010;117:S41-S45
28. Tsai CY, Lee SC, Hung CC, et al. False elevation of blood glucose levels measured by GDH-PQQ-based glucometers occurs during all daily dwells in peritoneal dialysis patients using icodextrin. Perit Dial Int 2010;30:329-335